RevoLix 2 μm激光联合吡柔比星治疗非肌层浸润性膀胱癌患者的临床疗效及其对VEGF水平的影响  

Clinical efficacy of Revo Lix 2 μm laser combined with pirarubicin in the treatment of non-muscular invasive bladder cancer and its effect on VEGF level

作　　者：李浩 米庆辉 高用军 祖雄兵[2] 

机构地区：[1]黔南州人民医院泌尿外科,贵州黔南州554000 [2]中南大学湘雅医院泌尿外科,湖南长沙410008

出　　处：《中国生化药物杂志》2015年第9期61-63,共3页Chinese Journal of Biochemical Pharmaceutics

基　　金：国家自然科学基金面上项目(81272838)

摘　　要：目的探讨Revo Lix 2μm激光联合吡柔比星治疗高龄非肌层浸润性膀胱癌患者的临床疗效及对患者血清血管内皮生长因子（vascular epithelial growth factor,VEGF）水平的影响。方法选取2012年1月~2013年4月于黔南州人民医院接受治疗的115例高龄非肌层浸润性膀胱癌患者作为研究对象,按照治疗方案分为A组（n=52）和B组（n=63）。A组给予膀胱肿瘤电切术＋盐酸吡柔比星30 mg＋5%葡萄糖注射液30 m L膀胱灌注治疗,每周1次,共8次。然后每月1次,共1年;B组给予Revo Lix 2μm激光膀胱肿瘤切除术＋盐酸吡柔比星30 mg溶于5%葡萄糖注射液30 m L膀胱灌注治疗,每周1次,共8次。然后每月1次,共1年。比较2组患者的手术情况、术后并发症发生率、治疗前后VEGF水平及复发率。结果与A组相比,B组术中出血量减少,尿管留置时间及住院时间缩短（P〈0.05）,手术时间2组间比较差异无统计学意义;术后B组并发症发生率为3.2%,明显低于A组的15.4%（P〈0.05）;入院时及术后1周时,2组患者VEGF水平比较差异无统计学意义;术后8周及术后6个月时,与A组相比,B组VEGF水平降低（P〈0.05）。随访2年,B组复发率为4.8%,明显低于A组的17.3%（P〈0.05）。结论 Revo Lix 2μm激光联合吡柔比星治疗高龄非肌层浸润性膀胱癌疗效可靠,术中出血量少,术后恢复较快且并发症发生率低,肿瘤复发率较低,这可能与降低患者的血清VEGF水平有关,尚需进一步研究证实。Objective To investigate curative efficacy of Revo Lix 2 μm laser in combined with pirarubicine in the treatment of non-muscular invasive bladder cancer and its effects on level of serum vascular endothelial growth factor（ VEGF）. Methods 115 cases with non-muscular invasive bladder cancer who received therapy in our hospital from January 2012 to April 2013 were selected as research objects to retrospectively analyze their materials. According to therapeutic schemes,patients were divided into group A（ n = 52） and group B（ n = 63）. Group A was given electrocision of bladder tumor and perfusion of pirarubicine 30 mg in 5% glucose injection 30 m L,one times per week,for eight weeks,and then one times per month,a total of one year; while group B was given Revo Lix 2 μm laser resection of bladder tumor and perfusion of pirarubicine 30 mg in 5% glucose injection 30 m L,one times per week,for eight week,and then one times per month,a total of one year. Then,operation status,incidence of complications after operation,level of VEGF and recurrence rate between the two groups were observed and compared. Results Compared with group A,group B had statistically less bleeding volume,shorter retention time of urinary tube and hospitalization time（ P〈0. 05）,while operation time in the two groups was statistically same. After operation,incidence of complications in group B was 3. 2%,which was statistically lower than that of 15. 4% in group A（ P〈0. 05）. On admission and 1 week after operation,levels of VEGF of two groups had no significant differences. 8 weeks and 6 months after operation,level of VEGF in group B was statistically lower than that in group A respectively（ P〈0. 05）. After the two-year follow-up,recurrence rate in group B was4. 8%,which was statistically lower than that of 17. 3% in group A（ P〈0. 05）. Conclusion Revo Lix 2 μm laser combined with pirarubicine is effective for patients with non-muscular invasive bladder cancer with less bleeding volume,quicker postoperative recover

关 键 词：REVO Lix 2ΜM激光 吡柔比星 非肌层浸润性膀胱癌 临床疗效 血管内皮生长因子 

分 类 号：R737.14[医药卫生—肿瘤]